Stepped-up Nucynta sales push starts paying off for Depomed

Depomed's ($DEPO) relaunch of the Nucynta franchise--purchased earlier this year from Johnson & Johnson ($JNJ)--is off to a running start, the company said last week with its Q3 earnings announcement. And it expects that momentum to carry it all the way to blockbuster land. More from FiercePharmaMarketing